TRAF4 Antibody [N23M6] | Primary Antibodies

Application: Reactivity: Human, Pig

Usage Information

Dilution
WB1:1000-1:6000 IHC1:200-1:800 IF1:50-1:500

Application
WB, IHC, IF, ELISA

Reactivity
Human, Pig

Source
Mouse Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
54 kDa 50-54 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight. Post-translational modifications(e.g., phosphorylation, glycosylation); Splice variants and isoforms; Relative charge; Multimerization.

Datasheet & SDS

Biological Description

Specificity
TRAF4 Antibody [N23M6] detects endogenous levels of total TRAF4 protein.

Clone
N23M6

Synonym(s)
TNF receptor-associated factor 4, Cysteine-rich domain associated with RING and Traf domains protein 1, Metastatic lymph node gene 62 protein (MLN 62), RING finger protein 83, TRAF4, CART1, MLN62, RNF83

Background
TRAF4 is a member of the tumor necrosis factor receptor–associated factor (TRAF) adaptor family that combines scaffold and E3 ubiquitin ligase functions and participates in signaling networks controlling morphogenesis, cell polarity, proliferation, survival, and inflammation. The protein contains N‑terminal RING and zinc‑finger motifs that confer ubiquitin ligase activity, followed by TRAF‑type coiled‑coil and C‑terminal TRAF domains that mediate homo‑ and hetero‑oligomerization and binding to receptor tails and signaling intermediates, and it also features nuclear localization signals that support localization to both cytoplasmic and nuclear compartments in specific contexts. TRAF4 associates with several receptor systems, including members of the TNF receptor–related family such as GITR and selected Toll‑like receptors, where it functions as an adaptor that promotes NF‑κB and MAPK pathway activation, often by recruiting or modulating other TRAFs and kinase complexes at receptor proximal sites. The adaptor also interacts with components of TGF‑β signaling, including TGF‑β receptors and Smad‑regulatory machinery, and enhances TGF‑β receptor signaling, which connects TRAF4 to transcriptional programs that regulate epithelial plasticity, migration, and invasive behavior in carcinoma cells. As an E3 ligase, TRAF4 catalyzes Lys‑48, Lys‑63, and other atypical ubiquitin linkages on substrates such as SMURF2, CHK1, and IRS1, which modulate proteasomal degradation, DNA damage checkpoint activation, and IGF pathway signal transduction, embedding TRAF4 into networks that govern osteogenic differentiation, cell cycle arrest, and metabolic signaling. TRAF4 is required during vertebrate embryogenesis for normal development of the axial skeleton, respiratory tract, and neural tube and contributes to epithelial tight junction organization and apical–basal polarity, thereby linking junctional complexes to downstream signaling that controls cell shape and tissue architecture. Expression of TRAF4 is low or restricted in many adult tissues but is consistently elevated in a broad range of carcinomas, frequently associated with gene amplification, and high TRAF4 levels correlate with enhanced TGF‑β and EGFR pathway activity, increased proliferation, and invasive or metastatic traits in breast and other epithelial cancers. TRAF4 also binds platelet receptors GPIbβ and GPVI and participates in platelet activation signaling, extending its adaptor and ubiquitin ligase functions to hemostatic and thrombotic processes.

Background

TRAF4 is a member of the tumor necrosis factor receptor–associated factor (TRAF) adaptor family that combines scaffold and E3 ubiquitin ligase functions and participates in signaling networks controlling morphogenesis, cell polarity, proliferation, survival, and inflammation. The protein contains N‑terminal RING and zinc‑finger motifs that confer ubiquitin ligase activity, followed by TRAF‑type coiled‑coil and C‑terminal TRAF domains that mediate homo‑ and hetero‑oligomerization and binding to receptor tails and signaling intermediates, and it also features nuclear localization signals that support localization to both cytoplasmic and nuclear compartments in specific contexts. TRAF4 associates with several receptor systems, including members of the TNF receptor–related family such as GITR and selected Toll‑like receptors, where it functions as an adaptor that promotes NF‑κB and MAPK pathway activation, often by recruiting or modulating other TRAFs and kinase complexes at receptor proximal sites. The adaptor also interacts with components of TGF‑β signaling, including TGF‑β receptors and Smad‑regulatory machinery, and enhances TGF‑β receptor signaling, which connects TRAF4 to transcriptional programs that regulate epithelial plasticity, migration, and invasive behavior in carcinoma cells. As an E3 ligase, TRAF4 catalyzes Lys‑48, Lys‑63, and other atypical ubiquitin linkages on substrates such as SMURF2, CHK1, and IRS1, which modulate proteasomal degradation, DNA damage checkpoint activation, and IGF pathway signal transduction, embedding TRAF4 into networks that govern osteogenic differentiation, cell cycle arrest, and metabolic signaling. TRAF4 is required during vertebrate embryogenesis for normal development of the axial skeleton, respiratory tract, and neural tube and contributes to epithelial tight junction organization and apical–basal polarity, thereby linking junctional complexes to downstream signaling that controls cell shape and tissue architecture. Expression of TRAF4 is low or restricted in many adult tissues but is consistently elevated in a broad range of carcinomas, frequently associated with gene amplification, and high TRAF4 levels correlate with enhanced TGF‑β and EGFR pathway activity, increased proliferation, and invasive or metastatic traits in breast and other epithelial cancers. TRAF4 also binds platelet receptors GPIbβ and GPVI and participates in platelet activation signaling, extending its adaptor and ubiquitin ligase functions to hemostatic and thrombotic processes.

References
https://pubmed.ncbi.nlm.nih.gov/23973329/ https://pubmed.ncbi.nlm.nih.gov/24212830/

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%